Key Takeaways
- Absci fell 8% today as AI drug discovery peers Schrödinger and Recursion slid in a Nasdaq sell-off.
- These stocks trade together on sentiment, so the drop says little about Absci’s business.
- Certara fell far less, a sign investors sold the pipeline-driven names hardest.
- Absci’s next test is proof-of-concept data for its hair-loss drug ABS-201, due by the end of 2026.
Absci (ABSI) fell 8% today, and it had company: Schrödinger (SDGR) dropped 10% and Recursion Pharmaceuticals (RXRX) lost 5% as tech stocks sold off, with the Nasdaq down big. None of the three put out news.
All three rallied together on Wednesday. Today, they gave it back. That’s a signal – sorry, I don’t make the rules.
They rise together, and they fall together
When three companies with different drugs move 9% or more the same way twice in one week, investors are trading the theme.
Certara’s smaller drop suggests they dumped the pipeline-driven names hardest. Its software revenue grew 4% in the second quarter, to $48.8 million, and software bookings rose 9%. Its report next week will show whether that demand is holding.
Schrödinger fits less neatly: its revenue grew 23% in 2025, to $255.9 million, yet it fell almost as hard as Absci. Its third-quarter report comes after the close on Nov. 4.
Recursion’s next catalyst comes sooner: it hosts a webinar on updated REC-4881 data on Tuesday, Nov. 3, less than three weeks after selling $200 million of new stock.
TIKR tracks 12 analysts on Absci. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Absci, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Absci’s Analyst Ratings
Nothing changed at Absci
Analysts expect Absci’s revenue to stay small, rising from $2.8 million in 2025 to $26.6 million in 2028:
So investors price the stock on ABS-201 and the mood around AI drug discovery. It traded at 242x forward sales at Thursday’s close, its highest in a year and nearly three times its 87x average:
Absci expects proof-of-concept data for ABS-201, its hair-loss drug, in the second half of 2026.
It had $201 million of cash and short-term investments at June 30, up from $126 million at March 31:
That’s plenty to reach the readout. A stock sale after strong data wouldn’t surprise me, though: Recursion paired its own clinical updates with one this month.
Wait for the data
At more than 200x forward sales, investors are already paying for a lot of success at ABS-201, so I’d wait for the data before buying this dip. Of course, strong results could make today’s price look cheap in a hurry.
So what is Absci stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Absci could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
